Arbutus Biopharma Corporation Share Price & Technical Analysis
ABUS · $4.23 (-0.70%)
Healthcare / Biotechnology
$4.23
-0.70%
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB…
Price chart
Seasonality
Jun has 1 positive and 4 negative years (last 5 years shown)
-4% return in Jun, -9% avg return in past 3 year Jun month.
-3% return in 2026, 35% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -16% | 15% | 0% | -7% | 10% | -4% | – | – | – | – | – | – | -3% |
| 25 | 0% | 6% | 3% | 0% | -6% | -9% | 6% | 12% | 22% | 2% | -6% | 12% | 42% |
| 24 | -4% | 17% | -7% | 4% | 26% | -9% | 23% | 8% | -3% | 0% | -8% | -6% | 41% |
| 23 | 30% | -7% | 11% | -17% | 0% | -8% | -4% | -9% | 0% | -10% | 11% | 25% | 23% |
| 22 | -28% | 14% | -6% | -23% | 0% | 13% | -15% | -4% | -14% | 21% | -4% | -4% | -51% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$835.58M
P/E ratio
5.1
52W high
$5.10
52W low
$3.04
Volume
5,25,770
Beta
0.62
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Arbutus Biopharma Corporation share price today?
- Arbutus Biopharma Corporation (ABUS) last traded around $4.23 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ABUS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ABUS. Download the app for real-time alerts.
- How can I analyze Arbutus Biopharma Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.